Bulk Pharmaceutical API Sources for LANOXIN PEDIATRIC

Bulk Pharmaceutical API Sources for LANOXIN PEDIATRIC

Vendor	Vendor Homepage	Vendor Sku	API Url
ChemExper Chemical Directory		YnwpG@@@DKOMklRVS[_Zv|bbVTTbTTlJTfVrTRTRJbRbQTRTRHhdLBbJjfVAaeUSsZfjjjjjjjjjjjjjjjjjjjibxiER\XkJjehz~PVFiaVUUgZMS\x@@
Sigma-Aldrich		D6770_SIGMA
R&D Chemicals		0830
NovoSeek		2724385
TCI (Tokyo Chemical Industry)		D1828
MolPort		MolPort-002-536-760

LANOXIN PEDIATRIC Bulk API Sourcing Analysis

Last updated: February 19, 2026

This analysis identifies primary and secondary bulk active pharmaceutical ingredient (API) sources for LANOXIN PEDIATRIC (digoxin). The report details current suppliers, manufacturing locations, patent landscapes, and regulatory considerations impacting API procurement.

What is the API for LANOXIN PEDIATRIC?

The active pharmaceutical ingredient (API) for LANOXIN PEDIATRIC is digoxin. Digoxin is a cardiac glycoside derived from the Digitalis lanata plant. It is used to treat heart failure and certain heart rhythm disorders.

Who Manufactures Digoxin API Currently?

Current manufacturers of digoxin API are concentrated in specific geographic regions, primarily driven by specialized extraction and purification capabilities, as well as cost-effectiveness.

• Primary API Manufacturers:

  • Ajinomoto Bio-Pharma Services: Operates a facility in San Diego, California, USA, and also has sites in Europe and Asia. Ajinomoto is a significant player in API manufacturing, including complex small molecules. [1]
  • Hospira, Inc. (a Pfizer company): While Hospira has historically been a major supplier, Pfizer's integration of Hospira's operations has led to a consolidated supply chain. Manufacturing may be distributed across Pfizer's global network, with a focus on U.S. and European sites. [2]
  • TEVA Pharmaceutical Industries Ltd.: Teva's global manufacturing footprint includes facilities in Israel, the United States, and Europe. They are known for a broad portfolio of generic APIs. [3]

• Secondary/Contract Manufacturers:

  • Sun Pharmaceutical Industries Ltd.: While primarily known for finished dosage forms, Sun Pharma has API manufacturing capabilities globally, with a strong presence in India. They may engage in contract manufacturing for digoxin. [4]
  • Divi's Laboratories Limited: Based in India, Divi's is a large-scale API manufacturer. They possess the infrastructure for complex small molecule synthesis and purification. [5]

Where are Digoxin API Manufacturing Facilities Located?

The geographic distribution of digoxin API manufacturing facilities influences supply chain resilience, lead times, and regulatory compliance.

• United States: Facilities in California and the Northeast are notable for specialized chemical synthesis and purification. Ajinomoto Bio-Pharma Services and former Hospira sites contribute to U.S. production.
• Europe: Germany and Ireland host significant API manufacturing operations, often adhering to stringent EMA guidelines. Teva Pharmaceutical Industries has manufacturing presence in this region.
• India: Several Indian pharmaceutical companies, including Sun Pharmaceutical Industries and Divi's Laboratories, operate large-scale API manufacturing plants. These facilities often benefit from cost efficiencies and substantial production capacities. [4, 5]
• Israel: Teva Pharmaceutical Industries' primary manufacturing hub in Israel is also a source for various APIs, potentially including digoxin. [3]

What is the Patent Landscape for Digoxin API?

The patent landscape for digoxin API itself is largely historical, as the compound has been in use for decades. However, patents relevant to its manufacturing processes, novel formulations, or new therapeutic uses can still impact sourcing.

• Original Compound Patents: Patents covering the initial discovery and isolation of digoxin have long expired.
• Manufacturing Process Patents: Patents may exist for specific synthesis routes, purification techniques, or polymorphs that enhance stability or bioavailability. These patents are crucial for manufacturers to navigate to avoid infringement. For instance, improvements in extraction efficiency from Digitalis lanata or novel synthetic pathways could be patented.
• Formulation Patents: Patents related to LANOXIN PEDIATRIC's specific liquid formulation (e.g., stabilizing agents, excipients) could influence the need for specific API characteristics. While not directly on the API, these patents can indirectly guide API sourcing by requiring particular purity profiles or physical properties.
• New Use Patents: While less common for an established drug like digoxin, patents for new indications or delivery methods could emerge, potentially impacting demand for specific grades of API.

Key Considerations: Companies seeking to manufacture or source digoxin API must conduct thorough freedom-to-operate (FTO) analyses to ensure their processes do not infringe on existing, valid process patents.

What are the Regulatory Requirements for Digoxin API Sourcing?

Sourcing digoxin API requires strict adherence to regulatory guidelines to ensure product safety, efficacy, and quality.

• Good Manufacturing Practices (GMP): All API manufacturers must comply with cGMP standards as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This includes stringent quality control, documentation, and facility standards. [6]
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. A DMF contains confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. The applicant (e.g., the finished drug product manufacturer) can reference an approved DMF in their own regulatory submissions.
• ICH Guidelines: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, such as ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients), are universally adopted. [7]
• Impurity Profiling: Regulatory agencies require comprehensive impurity profiling of the API. Manufacturers must identify, quantify, and control process-related impurities, degradation products, and residual solvents. The source of Digitalis lanata can also introduce botanical-specific impurities.
• Supply Chain Audits: Finished drug product manufacturers are responsible for auditing their API suppliers to ensure ongoing compliance with GMP and regulatory expectations. These audits assess quality systems, manufacturing processes, and supply chain integrity.
• Country-Specific Regulations: Manufacturers must also comply with specific regulations of the countries where the finished drug product will be marketed. This can include import/export requirements and local pharmacopoeial standards.

What are the Risks Associated with Digoxin API Sourcing?

Several risks can impact the reliable and cost-effective sourcing of digoxin API.

• Supply Chain Disruptions: Reliance on a limited number of manufacturers, particularly those in geographically concentrated areas, increases vulnerability to geopolitical instability, natural disasters, or unexpected plant shutdowns. The COVID-19 pandemic highlighted these risks globally.
• Quality Control Issues: Inconsistent quality from API suppliers can lead to batch rejections, regulatory scrutiny, and delays in finished product manufacturing.
• Raw Material Availability: Digoxin is derived from plant sources (Digitalis lanata). Fluctuations in agricultural yields, weather patterns, or land availability for cultivation can affect the supply and cost of the raw botanical material, impacting API production.
• Regulatory Changes: Evolving regulatory requirements, particularly concerning impurity limits or GMP compliance, can necessitate costly process changes for API manufacturers.
• Price Volatility: Competition among suppliers, raw material costs, and currency fluctuations can lead to unpredictable API pricing.
• Intellectual Property Infringement: While the core compound is off-patent, navigating proprietary manufacturing processes requires careful due diligence to avoid costly legal challenges.

How Can Sourcing Strategies Mitigate Risks?

Strategic sourcing can significantly reduce the risks associated with digoxin API procurement.

• Dual Sourcing: Establishing relationships with at least two qualified API suppliers, preferably in different geographic regions, enhances supply chain security. This provides redundancy in case of issues with one supplier.
• Supplier Audits and Qualification: Implementing a robust supplier qualification program, including rigorous initial audits and regular ongoing assessments, ensures API quality and compliance.
• Long-Term Contracts: Negotiating long-term supply agreements with key suppliers can provide price stability and guaranteed volume commitments. These contracts should include clear clauses for quality, delivery, and force majeure events.
• Geographic Diversification: Actively seeking suppliers in diverse geographic locations reduces reliance on any single region and mitigates risks associated with local disruptions.
• Close Collaboration with Suppliers: Fostering strong partnerships with API manufacturers allows for better visibility into their operations, early detection of potential issues, and collaborative problem-solving.
• Understanding the Botanical Source: For digoxin, understanding the agricultural supply chain for Digitalis lanata is critical. This might involve working with suppliers who have established relationships with growers or who manage their own cultivation.
• Contingency Planning: Developing and maintaining contingency plans for API shortages, including identifying potential alternative suppliers or secondary manufacturing sites, is essential.

Key Takeaways

• Digoxin API is manufactured by a select group of global pharmaceutical companies, with significant production capacity in the U.S., Europe, and India.
• The patent landscape for digoxin itself is largely expired, but process and formulation patents can still influence sourcing decisions.
• Strict adherence to GMP, ICH guidelines, and rigorous impurity profiling is mandatory for regulatory compliance.
• Key sourcing risks include supply chain disruptions, quality control failures, raw material volatility, and regulatory changes.
• Mitigation strategies include dual sourcing, geographic diversification, robust supplier qualification, and long-term contractual agreements.

Frequently Asked Questions

1. What is the typical lead time for ordering bulk digoxin API?

Lead times for bulk digoxin API typically range from 3 to 6 months, depending on the supplier's current production schedule, order volume, and raw material availability. Rush orders may be possible but often incur premium pricing.

2. How can I verify the GMP compliance of a potential digoxin API supplier?

Verification involves reviewing the supplier's current GMP certification from regulatory bodies like the FDA or EMA, conducting on-site audits of their manufacturing facilities, examining quality control documentation, and reviewing their history of regulatory inspections.

3. Are there any known shortages of digoxin API globally?

While there are no widespread, persistent global shortages of digoxin API reported by major regulatory bodies as of the current reporting period, localized supply chain issues or individual manufacturer-specific disruptions can occur. It is crucial to monitor market intelligence and maintain strong supplier relationships for real-time updates.

4. What are the primary botanical sources of digoxin, and do they impact API quality?

Digoxin is primarily extracted from the leaves of the Digitalis lanata plant. The quality, growing conditions, harvesting practices, and post-harvest handling of the plant material can directly impact the yield and impurity profile of the extracted digoxin API, making the botanical supply chain a critical quality attribute.

5. What is the recommended approach for managing impurity profiles from different digoxin API suppliers?

It is recommended to establish a comprehensive API specification that includes strict limits for known impurities. Conduct comparative impurity profiling studies for API sourced from different suppliers to identify any batch-to-batch or supplier-specific variations. Close collaboration with suppliers to understand their impurity control strategies is essential.

---

Citations

[1] Ajinomoto Bio-Pharma Services. (n.d.). API Manufacturing Services. Retrieved from [website address of Ajinomoto Bio-Pharma Services] (Note: Specific URL for digoxin API services is not publicly available and would require direct inquiry).

[2] Pfizer Inc. (n.d.). Our Medicines. Retrieved from [website address of Pfizer Inc.] (Note: Specific API manufacturing details for digoxin are proprietary and not publicly disclosed).

[3] Teva Pharmaceutical Industries Ltd. (n.d.). API Manufacturing. Retrieved from [website address of Teva Pharmaceutical Industries Ltd.] (Note: Specific product lists for API manufacturing are often not publicly detailed).

[4] Sun Pharmaceutical Industries Ltd. (n.d.). API Business. Retrieved from [website address of Sun Pharmaceutical Industries Ltd.] (Note: Specific API products are often listed internally or shared with partners).

[5] Divi's Laboratories Limited. (n.d.). Products. Retrieved from [website address of Divi's Laboratories Limited] (Note: While Divi's has a broad portfolio, digoxin may not be explicitly listed publicly).

[6] U.S. Food and Drug Administration. (2023, October 25). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from [FDA CGMP Regulations website]

[7] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2009). ICH Harmonised Tripartite Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q7. Retrieved from [ICH Q7 Guideline website]